United States, Feb. 2 -- GE HealthCare announced that Allia (TM) Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite. The latest Allia platform, one of the company's bold innovations first unveiled at the Radiological Society of North America's (RSNA) 2025 Annual Meeting, assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and surgical procedures. Allia Moveo delivers enhanced workflow through a compact, cable-free C-arm system with an intuitive user interface, and AI-powered guidance tools to help clinicians work efficiently and adapt to the spatial constraints of traditional interventional...